Check Out What’s New at Goldfinch

06.14.21

Goldfinch Bio to Present at the Raymond James Human Health Innovation Conference

05.13.21

Goldfinch Bio Initiates Phase 1 Clinical Trial of GFB-024, a Novel Precision Medicine Product Candidate for Patients with Severe Insulin Resistant Diabetic Nephropathy (DN)

04.20.21

Goldfinch Bio Expands Board of Directors with Appointments of Meryl Zausner, Hon. William “Mo” Cowan and Tyrell Rivers, Ph.D.

11.19.20

Goldfinch Bio Announces Appointment of Robin A. Walker, J.D., as Chief Legal Officer

10.22.20

Goldfinch Bio Presents Clinical Data from Phase 1 Trial Supporting Advancement of GFB-887 as a Precision Medicine for Patients with Kidney Diseases